Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (6): 953-957. doi: 10.19723/j.issn.1671-167X.2023.06.001
琼 扶,霜 叶*(
)
CLC Number:
- R593.2
| 1 |
Wang L , Wang FS , Gershwin ME . Human autoimmune diseases: A comprehensive update[J]. J Intern Med, 2015, 278 (4): 369- 395.
doi: 10.1111/joim.12395 |
| 2 |
Arbuckle MR , McClain MT , Rubertone MV , et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus[J]. N Engl J Med, 2003, 349 (16): 1526- 1533.
doi: 10.1056/NEJMoa021933 |
| 3 |
Furie RA , Aroca G , Cascino MD , et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial[J]. Ann Rheum Dis, 2022, 81 (1): 100- 107.
doi: 10.1136/annrheumdis-2021-220920 |
| 4 |
Baker DJ , Arany Z , Baur JA , et al. CAR T therapy beyond cancer: The evolution of a living drug[J]. Nature, 2023, 619 (7971): 707- 715.
doi: 10.1038/s41586-023-06243-w |
| 5 |
Maldini CR , Ellis GI , Riley JL . CAR T cells for infection, autoimmunity and allotransplantation[J]. Nat Rev Immunol, 2018, 18 (10): 605- 616.
doi: 10.1038/s41577-018-0042-2 |
| 6 | Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases[J/OL]. Lancet, (2023-09-22)[2023-10-12]. https://doi.org/10.1016/S0140-6736(23)01126-1. |
| 7 |
Mougiakakos D , Krönke G , Völkl S , et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus[J]. N Engl J Med, 2021, 385 (6): 567- 569.
doi: 10.1056/NEJMc2107725 |
| 8 |
Mackensen A , Müller F , Mougiakakos D , et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus[J]. Nat Med, 2022, 28 (10): 2124- 2132.
doi: 10.1038/s41591-022-02017-5 |
| 9 |
Zhang W , Feng J , Cinquina A , et al. Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR[J]. Stem Cell Rev Rep, 2021, 17 (6): 2120- 2123.
doi: 10.1007/s12015-021-10251-6 |
| 10 |
Qin C , Tian DS , Zhou LQ , et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: Phase 1 trial interim results[J]. Signal Transduct Target Ther, 2023, 8 (1): 5.
doi: 10.1038/s41392-022-01278-3 |
| 11 |
Müller F , Boeltz S , Knitza J , et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome[J]. Lancet, 2023, 401 (10379): 815- 818.
doi: 10.1016/S0140-6736(23)00023-5 |
| 12 |
Pecher AC , Hensen L , Klein R , et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome[J]. JAMA, 2023, 329 (24): 2154- 2162.
doi: 10.1001/jama.2023.8753 |
| 13 |
Bergmann C , Müller F , Distler JHW , et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells[J]. Ann Rheum Dis, 2023, 82 (8): 1117- 1120.
doi: 10.1136/ard-2023-223952 |
| 14 |
Granit V , Benatar M , Kurtoglu M , et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): A prospective, multicentre, open-label, non-randomised phase 1b/2a study[J]. Lancet Neurol, 2023, 22 (7): 578- 590.
doi: 10.1016/S1474-4422(23)00194-1 |
| 15 |
Ellebrecht CT , Bhoj VG , Nace A , et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease[J]. Science, 2016, 353 (6295): 179- 184.
doi: 10.1126/science.aaf6756 |
| 16 |
Sun Y , Yuan Y , Zhang B , et al. CARs: A new approach for the treatment of autoimmune diseases[J]. Sci China Life Sci, 2023, 66 (4): 711- 728.
doi: 10.1007/s11427-022-2212-5 |
| 17 |
Riet T , Chmielewski M . Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges[J]. Front Immunol, 2022, 13, 934343.
doi: 10.3389/fimmu.2022.934343 |
| [1] | Hui WEI, Jingfeng ZHANG, Zhongqiang YAO, Jinxia ZHAO. Clinical characteristics and relevant factors of rheumatoid arthritis patients with anemia of chronic disease [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 307-312. |
| [2] | Jiyan CHU, Ping LI, Jing TIAN, Diyu FU, Lin GUO, Rui SUN, Yadi LI. Expression of the melanoma 2-mediated pyroptosis pathway in peripheral blood mononuclear cells of patients with idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 175-183. |
| [3] | Yuan LIU, Guixiu SHI. Change from Sjögren syndrome to Sjögren disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1015-1017. |
| [4] | Yirui LIAN, Jingxuan LIU, Liang ZHAO, Jing ZHAO, Sitian ZANG, Yuhui LI. Rheumatic disease spectrum and immunological profile of anti-PM/Scl antibodies in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1018-1023. |
| [5] | Tao WU, Jianzi LIN, Yafeng ZHU, Jianda MA, Peiwen JIA, Lijuan YANG, jie PAN, Yaowei ZOU, Ying YANG, Ye LU, Lie DAI. Serum inter-alpha-trypsin inhibitor heavy chain H3 is identified as a potential biomarker for myopenia in patients with rheumatoid arthritis using proteomic profiling [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1024-1031. |
| [6] | Wenhao LIN, Yang XIE, Fangqing WANG, Shuying WANG, Xiangjun LIU, Fanlei HU, Yuan JIA. Single-cell RNA sequencing of B cells reveals molecular typing in Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1032-1041. |
| [7] | Zhao XIANG, Li YANG, Jing YANG. Untargeted metabolomics reveals differential serum metabolites and metabolic pathways in patients with primary Sjögren syndrome and thrombocytopenia [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1042-1050. |
| [8] | Yayun ZHAO, Mengfan NI, Xue LI, Bei WANG, Gong CHENG, Jing HE, Yuebo JIN. Clinical efficacy and safety of rituximab in treating renal injury in primary Sjögren syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1051-1060. |
| [9] | Jiajing PENG, Li CUI. Clinical features and prognosis of sarcoidosis with ocular lesions as the initial manifestation [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1061-1066. |
| [10] | Yajing GAO, Zhengfang LI, Mengsi MA, Lijun WU. Role of the SII and SIRI in risk prediction, disease activity assessment, and prog-nostic evaluation of Behçet disease uveitis [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1067-1073. |
| [11] | Xiaolin WANG, Shaoyi GUO, Dazhao CHEN, Xijie WEN, Yong HUA, Liang ZHANG, Qin ZHANG. A follow-up study on total hip arthroplasty in patients with systemic lupus erythematosus combined with osteonecrosis of femoral head [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1081-1088. |
| [12] | Xinfeng WU, Siliang MAN, Dazhao CHEN, Yong HUA, Xijie WEN, Yingyue DING, Liang ZHANG, Xiujuan HOU. A long-term review for radiographic parameters of hips in axial spondyloarthritis patients with end-stage hip involvement: A 24-year trend analysis from a single high-volume tertiary center [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1089-1095. |
| [13] | Jingwen LAN, Zhe CHEN, Yongjing CHENG, Like ZHAO. Clinical characteristics, efficacy and safety of antifibrotic agents in elderly patients with connective tissue disease-associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1101-1106. |
| [14] | Yanyan LI, Xiangjun LIU, Gongming LI, Chun LI, Yuan JIA. Clinic behavior and therapeutic status of patients with antiphospholipid syndrome [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1107-1112. |
| [15] | Chun WEI, Yue YANG, Xinju ZHAO, Xu LIU, Yuan JIA. Systemic lupus erythematosus complicated by autoimmune nodopathy: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1174-1179. |
|
||